Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2023-12-04 00:00:00 ET · period of report 2023-11-30 · accession 0000950170-23-067738 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-04 | 2023-11-30+ | KRSA | Hecht Peter M | Dir, 10% | A - Grant | $0.00 | +35.0K | 362.4K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-30 | A | A | 20,000 | $0.00 | 347,385 | D | — | — | (F1) The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of the shares vest immediately and the remaining 17,500 shares are subject to vesting ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |
| 2 | Common | Common Stock | 2023-12-01 | A | A | 15,000 | $0.00 | 362,385 | D | — | — | (F2) The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 48- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |